Articles On Orthocell (ASX:OCC)

ASX 200 closes 0.13% lower on Friday, despite eight of 11 sectors higher  Tech sector leads gains while resource stocks weigh heavily Trigg Minerals continues to progress its proposed US Nasdaq listing    The ASX 200 ended the week lower...

Now could be a good time to pounce on the ASX 200 stock in this article. That's the view of analysts at Bell Potter, which believe that market-beating returns could be on the cards for investors over the next 12 months. Which ASX 200 stock?...

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up a fraction to 8,971.3 points. Four ASX shares that are rising more than most today are listed b...

Very few investors had heard of Dateline Resources Ltd (ASX: DTR) at the start of the year. In early January, shares in this ASX mining stock were changing hands at $0.003 per share, with its market capitalisation clocking in at less th...

ASX gold shares are having an incredible run in 2025 amid the gold price soaring above US$4,000 per ounce for the first time overnight. At the time of writing, the gold price is US$4,011 per ounce, representing an astonishing 53% gain i...

Local tech titans are being given a platform for their achievements at the upcoming EY Entrepreneur Of The Year™ awards on October 15. The founders of Employment Hero, Tiimely, Pay.com.au and Orthocell will go head to head in the Technology...

The S&P/ASX 200 Index (ASX: XJO) is climbing higher today, up 1.27% at the time of writing. For the year, it is 9.27% higher. It's decent growth for the past 12-month period, but there is one stock that has far outpaced the index and...

  Orthocell achieves record revenue of $3 million for Q1 FY26, up 9.1% on previous record in Q4 FY25 Revenue driven primarily by increasing market penetration of flagship nerve repair product Remplir in existing markets Sixth consecutive q...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 8,935.9 points. Four ASX shares that have failed to follow the market higher today are l...

The S&P/ASX 200 Index (ASX: XJO) is back on form and racing higher on Thursday. In afternoon trade, the benchmark index is up 1.05% to 8,939.4 points. Four ASX shares that are rising more than most today are listed below. Here's why t...

Impedimed and Avita Medical have won a ‘pay rise’ from private and public US payors Orthocell posts record revenue – an entrée perhaps, with US sales main course to come  Gut disorders house Immuron outlines a packed October schedule   Fe...

Superannuation fund research house Chantwest has teamed up with retirement educator Bec Wilson on a new rating – the Epic Retirement Tick – and the bad news is only six out of Australia's more than 60 super funds have made the grade....

The All Ordinaries Index (ASX: XAO) is up 0.6% today, with ASX All Ords stock Orthocell Ltd (ASX: OCC) leaping ahead of those gains. Shares in the regenerative medicine company closed yesterday trading for $1.435. In early morning trade on...

At the time of writing, there are roughly 380 ASX ETFs for investors to choose from.  However, in recent years, there has been more and more with more specific themes like AI, tech, or sustainability. Other times, new ETFs come...

The S&P/ASX 200 Index (ASX: XJO) is out of form and on course to record a decline. At the time of writing, the benchmark index is down 0.4% to 8,811.4 points. Four ASX shares that are not letting that hold them back are listed below. H...

The S&P/ASX 200 Index (ASX: XJO) had a volatile and ultimately unsuccessful Tuesday session today. After spending time in both positive and negative territory this session, the bears won out in the e...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.1% to 8,872 points. Four ASX shares that are rising more than most today are listed below. He...

While global headlines are dominated by trillion-dollar giants, one ASX small cap is quietly making big strides in artificial intelligence. AI-Media Technologies Ltd (ASX: AIM) has built its business on live captioning and translation servi...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully unpacks the latest news from Orthocell (ASX:OCC), who has appointed its first Canadian distributor for Remplir, as it pu...

Restaurant Brands New Zealand Ltd (ASX: RBD) has received a takeover offer from its majority shareholder at a massive 64% premium to the last trading price. The company, whose Australian-listed shares were valued at $336.8 million at Mon...

Orthocell Ltd (ASX: OCC) shares are having a strong start to the day. In morning trade, the small cap ASX share is up over 8% to $1.35. Why is this ASX share jumping on Tuesday? Investors have been bidding the regenerative medicine company'...

You make your own luck – and 4D Medical (ASX:4DX) has enjoyed that commodity in shovel-loads over the last month. It all started in August when the lung scanning innovator inked a deal with the giant ASX-listed Pro Medicus, involving a $10...

ASX crawls up just 0.17pc with 7 sectors lower Healthcare sharply lower as Trump threatens tariffs on pharmaceuticals Strength in resources and banks outweighs greater market losses   Markets take stock as tariffs fire back up After a pol...

Management “couldn’t be happier” with the early US rollout of its flagship device, Remplir Revenue should start slowly but then escalate rapidly in ‘hockey stick’ style Following Remplir’s surprise adoption in prostate surgery, Orthocell e...

FDA classifies medical devices based on the type of device and the level of risk it poses Three main FDA clearances for medical devices are 510(k), de novo and pre-market approval  Several ASX companies have recently been granted FDA clear...

DroneShield Ltd (ASX: DRO) shares were trading more than 3% higher on Tuesday after the company said it had now sold more than 4000 systems worldwide. The anti-drone technology company said in a statement to the ASX that it had passed th...

ASX closes in the green on positive trading day for energy and resources Big-gun miners help bring bourse back out of the tunnel Goldies rally, too – and we may as well keep this bullet point as standard for the moment   The ASX closed 0....

Good Afternoon and Welcome to HotCopper’s Market Close for Tuesday 16 September, I’m Jon Davidson. The index came back to life on Tuesday after Wall Street notched fresh records overnight, US futures just in the green once more in the f...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Potential to reduce the risk of erectile dysfunction and urinary incontinence PERTH,...

Australian urologists are now using Orthocell’s flagship nerve repair product during prostate cancer surgery in what the WA biotech says has potential to reduce the risks of erectile dysfunction.

Orthocell Ltd (ASX: OCC) shares are outperforming the market on Tuesday. The ASX All Ords stock is currently up 10% to $1.21. This follows the regenerative medicine company announcing a major new application for its flagship nerve repair de...

Orthocell (ASX:OCC) shares popped +10% on Tuesday as the company reported its flagship nerve repair product, Remplir, is being used by some Australian urologists in seeking to mitigate complications that typically follow prostate cancer sur...

Australian urologists are using Orthocell’s flagship nerve repair product Remplir in prostate cancer surgery Remplir holds promise in reducing post-surgical complications due to peripheral nerve injury Up to 80% of men experience erectile...

Regenerative medicine company Orthocell (ASX: OCC) has introduced its flagship nerve repair device Remplir to Australian urologists for use in nerve-sparing robotic-assisted radical prostatectomies (RARP). Currently up to 80% of men experie...

The All Ordinaries Index (ASX: XAO) has gained 4.0% since market close on 9 July, but one ASX All Ords stock has left those gains in the dust. The surging stock in question is respiratory imaging technology company 4DMedical Ltd (ASX: 4DX)....

DroneShield Ltd (ASX: DRO) shares are tumbling today. Shares in the S&P/ASX 300 Index (ASX: XKO) drone defence company – which will join the S&P/ASX 200 Index (ASX: XJO) on 22 September – closed yesterday trading for $3.21. In early...

The S&P/ASX 200 Index (ASX: XJO) is having a better session on Wednesday. In afternoon trade, the benchmark index is up 0.3% to 8,828.3 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's...

S&P/ASX 200 Index (ASX: XJO) stocks are up 0.27% to 8,827.1 points on Wednesday. The ASX 200 has slipped 1.6% since the start of what is traditionally a weaker month for the market. On The Bull this week, experts have identified f...

Tylah Tully chats with Orthocell (ASX:OCC) CEO and managing director Paul Anderson after a new real-world study demonstrated a 81.1% treatment success rate for the company’s nerve repair device, Remplir. Anderson explains why this real-worl...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Data to support US sales roll out and EU + UK regulatory submissions  Interim resu...

ASX closes 0.24% lower on Monday with tech leading gainers and energy the laggards Asian markets climb higher led by Tokyo after Japanese Prime Minister Shigeru Ishiba announces resignation Supermarket giants Coles and Woolworths face heft...

Interim results from Orthocell’s new Remplir study demonstrate treatment success rate of 81.1% following nerve repair procedures Results confirm Remplir as ideal for connecting severed nerves, protecting damaged nerves or capping nerves af...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully looks at Orthocell (ASX:OCC), whose nerve repair product Remplir is continuing its strong US market momentum with increa...

Avita shares jump up to 13% after the company’s $23 million equity raising   EBR Systems narrows June quarter loss Orthocell is on track with its US rollout   Burns and woundcare outfit Avita Medical (ASX:AVH) has answered concerns about...

Despite myriad pressures under the Trump regime, the FDA’s drug and device approval process largely has been unfettered Telix Pharmaceuticals expects a company-making approval decision by the end of the month Painchek is among a string of...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights Orthocell announces director resignation due to health, maintains advisory support Lanthanein completes drilling phase at Lady Grey Project in Western Australia Aurum and Asian Battery Metals report progress acros...

  Experienced corporate leader Michael McNulty will join the board as a non-executive director and chair of audit committee US-based independent non-executive director Dr Ravi Thadhani elevated to lead independent director Former oppositio...